Azitra, Inc. to Present at European Dermatology and Venereology Congress

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced a significant forthcoming presentation about ATR-04. Dr. Mary Spellman will deliver this late-breaking presentation on Thursday, September 26, 2024, during the European Academy of Dermatology and Venereology (EADV) Congress 2024 held in Amsterdam. The presentation, titled “Development of a Staphylococcus epidermidis strain for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity,” will provide insights into the innovative treatment approach Azitra is developing.

ATR-04 is a live biotherapeutic product engineered from a strain of Staphylococcus epidermidis, originally sourced from a healthy individual. To enhance safety, the strain has been modified to remove an antibiotic resistance gene and has been engineered for auxotrophy, which limits its growth under certain conditions. ATR-04 is intended to address skin toxicity caused by EGFR inhibitors (EGFRis). This toxicity occurs due to the suppression of skin immunity and results in inflammation, often accompanied by increased levels of IL-36γ and Staphylococcus aureus. In the United States alone, approximately 150,000 patients experience skin toxicity from EGFR inhibitors annually.

Azitra is actively pursuing a multicenter, randomized, controlled Phase 1/2 clinical trial for ATR-04, targeting patients suffering from EGFR inhibitor-induced dermal toxicity. The U.S. Food and Drug Administration (FDA) has granted ATR-04 Fast Track designation, which expedites the review process for therapies that address unmet medical needs. The oral presentation by Dr. Spellman will highlight the preclinical development of ATR-04 and discuss the details of the planned Phase 1/2 clinical trial.

Further details from the presentation will be accessible on Azitra’s official website.

Azitra, Inc., an emerging clinical biopharmaceutical entity, is dedicated to advancing precision dermatology treatments through engineered proteins and topical live biotherapeutic products. The company boasts a proprietary platform that includes a comprehensive microbial library with around 1,500 unique bacterial strains. These strains are screened for their therapeutic potential using advanced artificial intelligence and machine learning technologies. Initially, Azitra is focusing on genetically modifying strains of Staphylococcus epidermidis, which it has identified as an ideal candidate for developing dermatological therapies.